Skip to main content

Table 6 Total specific costs during follow-up

From: Estimates of epidemiology, mortality and disease burden associated with progressive fibrosing interstitial lung disease in France (the PROGRESS study)

 

PF-ILD (n = 14,413)

Mean, € (SD)

Median, € (IQR)

Cost per patient

43,807 (57,904)

25,613 (10,622–54,287)

Annual cost per patient

81,286 (21,935)

18,362 (6,856–52,026)

  1. End of follow-up was defined as the earliest of patient death, end of study period (31 December 2017) or last available record (hospitalisation, consultation or healthcare reimbursement) in the data source. Patients with a data gap persisting beyond 12 months are considered to have their follow-up ceased at their last record. Costs were based on non-hospital medical procedures (CCAM). Respiratory tests performed during a hospital stay were not taken into account contrary to indicators
  2. CCAM classification commune des actes médicaux [medical classification for clinical procedures], IQR interquartile range, PF-ILD progressive fibrosing interstitial lung disease, SD standard deviation